Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

Lawrence Blonde; Johan Jendle; Jorge Gross; Vincent Woo; Honghua Jiang; Jessie L Fahrbach; Zvonko Milicevic

doi:10.1016/s0140-6736(15)60936-9

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

The Lancet ◽

10.1016/s0140-6736(15)60936-9 ◽

2015 ◽

Vol 385 (9982) ◽

pp. 2057-2066 ◽

Cited By ~ 122

Author(s):

Lawrence Blonde ◽

Johan Jendle ◽

Jorge Gross ◽

Vincent Woo ◽

Honghua Jiang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Lispro ◽

Open Label ◽

Phase 3 ◽

Prandial Insulin ◽

Open Label Phase

Download Full-text

Decision letter for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v1/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v1/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Author response for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v2/response1 ◽

2020 ◽

Author(s):

Tina Vilsbøll ◽

Ella Ekholm ◽

Eva Johnsson ◽

Ricardo Garcia‐Sanchez ◽

Nalina Dronamraju ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Author Response ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13981 ◽

2020 ◽

Vol 22 (6) ◽

pp. 957-968

Author(s):

Tina Vilsbøll ◽

Ella Ekholm ◽

Eva Johnsson ◽

Ricardo Garcia‐Sanchez ◽

Nalina Dronamraju ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v1/review3 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v2/review1 ◽

2020 ◽

Author(s):

Afshin Salsali

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Decision letter for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v1/review2 ◽

2019 ◽

Author(s):

Iouri Bachmakov

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

The Lancet ◽

10.1016/s0140-6736(10)62305-7 ◽

2011 ◽

Vol 377 (9769) ◽

pp. 924-931 ◽

Cited By ~ 89

Author(s):

Bernard Zinman ◽

Greg Fulcher ◽

Paturi V Rao ◽

Nihal Thomas ◽

Lars A Endahl ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Insulin Degludec ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Long Acting

Download Full-text

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Diabetes Care ◽

10.2337/dc14-0001 ◽

2014 ◽

Vol 37 (8) ◽

pp. 2317-2325 ◽

Cited By ~ 143

Author(s):

Julio Rosenstock ◽

Vivian A. Fonseca ◽

Jorge L. Gross ◽

Robert E. Ratner ◽

Bo Ahrén ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Lispro ◽

Basal Insulin ◽

Receptor Agonist ◽

Prandial Insulin ◽

Oral Agents ◽

Insulin Replacement

Download Full-text